| Original language | English |
|---|---|
| Pages (from-to) | 200-201 |
| Number of pages | 2 |
| Journal | Schizophrenia Research |
| Volume | 174 |
| Issue number | 1-3 |
| DOIs | |
| Publication status | Published - 2016 Jul 1 |
Keywords
- Adverse events
- Clozapine
- Schizophrenia
- Side effects
- Subjective
ASJC Scopus subject areas
- Psychiatry and Mental health
- Biological Psychiatry
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Consistency between clinician and patient ratings of clozapine-induced side effects. / Takeuchi, Hiroyoshi; Fervaha, Gagan; Remington, Gary.
In: Schizophrenia Research, Vol. 174, No. 1-3, 01.07.2016, p. 200-201.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Consistency between clinician and patient ratings of clozapine-induced side effects
AU - Takeuchi, Hiroyoshi
AU - Fervaha, Gagan
AU - Remington, Gary
N1 - Funding Information: Dr. Takeuchi is supported through the Canadian Institutes of Health Research (CIHR) Fellowship program. This funding source had no role in study design, statistical analysis or interpretation of findings, or in manuscript preparation or submission for publication. Data used in the preparation of this article were obtained from the limited access datasets (Version 1) distributed from the NIH-supported “Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia” (CATIE-Sz). This is a multisite, clinical trial of persons with schizophrenia comparing the effectiveness of randomly assigned medication treatment. The study was supported by NIMH Contract #N01MH90001 to the University of North Carolina at Chapel Hill. The ClinicalTrials.gov identifier is NCT00014001 . This manuscript reflects the views of the authors and may not reflect the opinions or views of the CATIE-Sz Study Investigators or the NIH. Funding Information: Dr. Takeuchi is supported through the Canadian Institutes of Health Research (CIHR) Fellowship program. This funding source had no role in study design, statistical analysis or interpretation of findings, or in manuscript preparation or submission for publication.Data used in the preparation of this article were obtained from the limited access datasets (Version 1) distributed from the NIH-supported ?Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia? (CATIE-Sz). This is a multisite, clinical trial of persons with schizophrenia comparing the effectiveness of randomly assigned medication treatment. The study was supported by NIMH Contract #N01MH90001 to the University of North Carolina at Chapel Hill. The ClinicalTrials.gov identifier is NCT00014001. This manuscript reflects the views of the authors and may not reflect the opinions or views of the CATIE-Sz Study Investigators or the NIH. Funding Information: Dr. Takeuchi has received fellowship grants from Centre for Addiction and Mental Health (CAMH) Foundation, the Japanese Society of Clinical Neuropsychopharmacology, and Astellas Foundation for Research on Metabolic Disorders, and manuscript fees from Dainippon Sumitomo Pharma. Mr. Fervaha has no competing interests to disclose. Dr. Remington has received research support from Novartis, Medicure and Neurocrine Bioscience, consultant fees from Laboratorios Farmacéuticos ROVI, Synchroneuron and Novartis, and speaker's fees from Novartis.
PY - 2016/7/1
Y1 - 2016/7/1
KW - Adverse events
KW - Clozapine
KW - Schizophrenia
KW - Side effects
KW - Subjective
UR - http://www.scopus.com/inward/record.url?scp=84963641179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963641179&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2016.04.005
DO - 10.1016/j.schres.2016.04.005
M3 - Letter
C2 - 27091657
AN - SCOPUS:84963641179
VL - 174
SP - 200
EP - 201
JO - Schizophrenia Research
JF - Schizophrenia Research
SN - 0920-9964
IS - 1-3
ER -